CT
The startup develops gene therapy vectors that target neurodegenerative diseases by halting and potentially reversing the toxic protein functions associated with conditions like amyotrophic lateral sclerosis and frontotemporal dementia. This approach aims to reduce neurotoxicity and neuronal loss, offering a pathway to effective treatments for affected patients.
Sheffield, United Kingdom
Updated 2 months ago
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops gene therapy vectors that target neurodegenerative diseases by halting and potentially reversing the toxic protein functions associated with conditions like amyotrophic lateral sclerosis and frontotemporal dementia. This approach aims to reduce neurotoxicity and neuronal loss, offering a pathway to effective treatments for affected patients.